Cryo-Cell International (NYSEAMERICAN:CCEL) Stock Price Crosses Above Fifty Day Moving Average – Here’s Why

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL)’s stock price crossed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $3.57 and traded as high as $3.79. Cryo-Cell International shares last traded at $3.79, with a volume of 659 shares changing hands.

Cryo-Cell International Stock Performance

The firm has a market capitalization of $30.63 million, a P/E ratio of -11.51 and a beta of 0.48. The firm has a 50 day moving average price of $3.58 and a two-hundred day moving average price of $3.49.

Cryo-Cell International (NYSEAMERICAN:CCEL) last announced its earnings results on Tuesday, April 14th. The company reported $0.01 earnings per share (EPS) for the quarter. The company had revenue of $7.68 million for the quarter.

Institutional Trading of Cryo-Cell International

An institutional investor recently bought a new position in Cryo-Cell International stock. Susquehanna International Group LLP bought a new position in Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned 0.14% of Cryo-Cell International at the end of the most recent reporting period. 10.44% of the stock is owned by institutional investors.

About Cryo-Cell International

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.